Infectious Disease Diagnostics Market Share, Covid-19 Impact Analysis, Report And Forecast 2027

Global Infectious Disease Diagnostics Market - Analysis of Market Size, Share & Trends for 2019 – 2020 and Forecast to 2027

Published: Aug-2021	Report ID: MEDE2105	Pages: 1 - 232	Formats^*:
Category : Medical Devices

The global infectious disease diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to reach 41.6 billion by 2027. The growth is primarily attributed to prevalence of infectious diseases, global outbreak of COVID-19, technological advancements, and increased demands for decentralized diagnostic POC kits. However, unfavourable and inadequate reimbursement scenarios can impact the growth of the market.

Get more information on this report: Download Free Sample PDF

Product: Reagents, kits and Consumables dominated the infectious disease diagnostics market in 2020

Reagents, kits and consumables segment accounted for the largest share of infectious disease diagnostics market. The largest share of this segment is mainly attributed to frequent purchase of these products due to their recurrent usage.

POC testing segment to account for fastest growth

By type of testing, infectious disease diagnostics market is segmented into laboratory testing and POC testing. During the forecast period, POC testing accounted for fastest growth. Highest CAGR can be attributed to faster diagnosis and need to closely monitor patients.

By Technology: Immunodiagnostics segment accounted for largest share

On the basis of technology, infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays and other technologies. Immunodiagnostics segment accounted for largest share in 2020. The growth of this segment was mainly attributed to increasing demand for immunoassays in COVID-19 testing, POC infectious disease testing, rising trend for automation and development of immunodiagnostic tests.

By Disease: Hepatitis to hold the largest share of Infectious disease diagnostics market

By disease type, hepatitis segment held the largest share of infectious disease diagnostics market in 2020. The growth is mainly driven by increasing blood transfusions and donations, prevalence of hepatitis B & C infections, rising geriatric population and benefits offered by POC instruments and kits.

Diagnostic laboratory: Accounted for largest share of Infectious disease diagnostics market

By end user, diagnostic laboratory segment accounted for highest CAGR. This can be attributed to strengthening of healthcare infrastructure and prevalence of infectious disease.

By Region: Asia Pacific fastest growing market

In 2020, North America accounted for the largest share of infectious disease diagnostics. The largest share is mainly attributed to highly developed healthcare system in US and Canada, availability of leading national clinical laboratories and technologically advanced instruments. However, Asia Pacific region is expected to grow at fastest CAGR during the forecast period. The growth is driven by rapid urbanization, government initiatives, increased investments on healthcare system and improved accessibility to diagnostic services.

Competitive Scenario

Abbott Laboratories (US)
F. Hoffmann-La Roche Ltd(Switzerland)
bioMÃ©rieux SA (France)
Thermo Fisher Scientific Inc. (US)
Danaher Corporation (US)
Quidel Corporation (US)
Hologic, Inc. (US)
Siemens Healthineers AG (Germany)
Becton, Dickinson and Company (US)
PerkinElmer Inc. (US)
QIAGEN (Netherlands)
Grifols S.A. (Spain)
DiaSorin S.p.A (Italy)
Bio-Rad Laboratories Inc. (US)
Sysmex Corporation (Japan)
Ortho Clinical Diagnostics (US)
Luminex Corporation (US)
Meridian Bioscience (US)
Genetic Signatures (Australia)
OraSure Technologies (US)
Trinity Biotech Plc. (Ireland)
Chembio Diagnostic Systems
Inc. (US)
Seegene Inc. (South Korea)
Co-Diagnostics Inc. (US)
ELITechGroup (France)
Epitope Diagnostics, Inc. (US)
Trivitron Healthcare (India)
Meril Life Sciences Pvt. Ltd. (India)
InBios International Inc. (US)
and ABACUS Diagnostica Oy (Finland)

1. Introduction

2. Research Methodology

3. Executive Summary

4. Premium Insights

5. Market Overview

5.1. Introduction
5.2. Market Dynamics

5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges

5.3. COVID-19 Impact of the Infectious Disease Diagnostics Market

6. Industry Insights

6.1. Introduction
6.2. Industry Trends

7. Global Infectious Disease Diagnostics Market, By Product, 2019-2027 (USD Million)

7.1. Introduction
7.2. Reagents, kits & consumables
7.3. Instruments
7.4. Software & services

8. Global Infectious Disease Diagnostics Market, By Type of testing, 2019-2027 (USD Million)

8.1. Laboratory Testing
8.2. POC Testing

9. Global Infectious Disease Diagnostics Market, By Technology, 2019-2027 (USD Million)

9.1. Immunodiagnostics
9.2. Clinical Microbiology
9.3. PCR
9.4. INAAT
9.5. DNA Sequencing & NGS
9.6. DNA Microarrays
9.7. Other Technologies

10. Global Infectious Disease Diagnostics Market, By Disease Type, 2019-2027 (USD Million)

10.1. COVID-19
10.2. HIV
10.3. HAIs
10.4. Hepatitis
10.5. CT/NG
10.6. HPV
10.7. TB
10.8. Influenza
10.9. Other Infectious Diseases

11. Global Infectious Disease Diagnostics Market, By End User, 2019-2027 (USD Million)

11.1. Diagnostics Laboratories
11.2. Hospitals & Clinics
11.3. Academic Research Institutes
11.4. Other End Users

12. Global Infectious Disease Diagnostics Market, By Geography, 2019-2027 (USD Million)

12.1. North America

12.1.1. US
12.1.2. Canada

12.2. Europe

12.2.1. Germany
12.2.2. UK
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Rest of Europe

12.3. Asia-Pacific

12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Rest of Asia-Pacific

12.4. Rest of the World

12.4.1. Latin America
12.4.2. Middle East & Africa

13. Competitive Landscape

13.1. Introduction
13.2. Market Share Analysis
13.3. Competitive Situation and Trends

13.3.1. Product Launches
13.3.2. Partnerships, Collaborations and Agreements
13.3.3. Acquisitions
13.3.4. Expansions
13.3.5. Other Developments

14. Company Profiles

14.1. Abbott Laboratories (US)
14.2. F. Hoffmann-La Roche Ltd (Switzerland)
14.3. bioMÃ©rieux SA (France)
14.4. Thermo Fisher Scientific Inc. (US)
14.5. Danaher Corporation (US)
14.6. Quidel Corporation (US)
14.7. Hologic, Inc. (US)
14.8. Siemens Healthineers AG (Germany)
14.9. Becton, Dickinson and Company (US)
14.10. PerkinElmer Inc. (US)
14.11. QIAGEN (Netherlands)
14.12. Grifols S.A. (Spain)
14.13. DiaSorin S.p.A (Italy)
14.14. Bio-Rad Laboratories, Inc. (US)
14.15. Sysmex Corporation (Japan)
14.16. Ortho Clinical Diagnostics (US)
14.17. Luminex Corporation (US)
14.18. Meridian Bioscience (US)
14.19. Genetic Signatures (Australia)
14.20. OraSure Technologies (US)
14.21. Trinity Biotech Plc. (Ireland)
14.22. Chembio Diagnostic Systems, Inc. (US)
14.23. Seegene Inc. (South Korea)
14.24. Co-Diagnostics, Inc. (US)
14.25. ELITechGroup (France)
14.26. Epitope Diagnostics, Inc. (US)
14.27. Trivitron Healthcare (India)
14.28. Meril Life Sciences Pvt. Ltd. (India)
14.29. InBios International, Inc. (US)
14.30. ABACUS Diagnostica Oy (Finland).

15. Appendix

15.1. Discussion Guide
15.2. Available Customizations
15.3. Related Reports

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1